Showing 6911-6920 of 10039 results for "".
- DNA to Host Annual Meeting in Orlando, May 1-4https://practicaldermatology.com/news/20140414-dna_to_host_annual_meeting_in_orlando_may_1-4/2459272/The Dermatology Nurses' Association (DNA) will host its 32nd Annual Convention at the Walt Disney World Swan and Dolphin in Orlando, Fla., May 1-4. The convention offers educational tracks in Pediatric Dermatology, Cosmetic Dermatology, Wound Management, Professional Practice, Medical Dermatology, D
- SkinCeuticals Announces the Launch of its First US Flagship Locationhttps://practicaldermatology.com/news/20140414-skinceuticals_announces_the_launch_of_its_first_us_flagship_location/2459274/SkinCeuticals launched SkinCeuticals Advanced Clinical Spa with Manhattan Dermatology and Cosmetic Surgery, the first flagship location. An exclusive Integrated Skincare treatment menu has been created, featuring comprehensive offerings that range from clinical procedures to
- TetraLogic Acquires Shape Pharmaceuticals, Inc.https://practicaldermatology.com/news/20140407-tetralogic_acquires_shape_pharmaceuticals_inc/2459275/TetraLogic Pharmaceuticals Corporation has entered an agreement to acquire Shape Pharmaceuticals, a biotechnology company. Shape Pharmaceuticals is developing SHAPE, which is a tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma.
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents.
- Lithera to Present at the 13th Annual Needham Healthcare Conferencehttps://practicaldermatology.com/news/20140402-lithera_to_present_at_the_13th_annual_needham_healthcare_conference/2459280/Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April
- April is Rosacea Awareness Monthhttps://practicaldermatology.com/news/20140401-april_is_rosacea_awareness_month/2459281/April is Rosacea Awareness Month and the National Rosacea Society encourages physicians and patients to raise awareness of the disease and its impact on affected individuals. This red-face disorder affects more than 16 million Americans between the ages of 30 and 60. It covers the spectru
- Cosmetic Treatments Jump 25 Percent in 2013: ASDS Surveyhttps://practicaldermatology.com/news/20140401-cosmetic_treatments_jump_25_percent_in_2013_asds_survey/2459283/The number of cosmetic procedures performed by members of the American Society for Dermatologic Surgery jumped to nearly 6.5 million in 2013 – an increase of 25 percent over the previous year, the ASDS Survey on Dermatologic Procedures shows.
- International Society of Hair Restoration Surgery Achieves ACCME Accreditation With Commendation for Educational Activitieshttps://practicaldermatology.com/news/20140401-international_society_of_hair_restoration_surgery__achieves_accme_accreditation_with_commendation_for_educational_activities/2459284/The International Society of Hair Restoration Surgery (ISHRS) – the largest international medical association of hair restoration surgeons – announced today that the Accreditation Council for Continuing Medical Education (ACCME) awarded the ISHRS Accreditation with Commendation for six years as a pr
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo